232 related articles for article (PubMed ID: 22988093)
1. Selective requirement for Mediator MED23 in Ras-active lung cancer.
Yang X; Zhao M; Xia M; Liu Y; Yan J; Ji H; Wang G
Proc Natl Acad Sci U S A; 2012 Oct; 109(41):E2813-22. PubMed ID: 22988093
[TBL] [Abstract][Full Text] [Related]
2. T-cells null for the MED23 subunit of mediator express decreased levels of KLF2 and inefficiently populate the peripheral lymphoid organs.
Kasper LH; Fukuyama T; Brindle PK
PLoS One; 2014; 9(7):e102076. PubMed ID: 25054639
[TBL] [Abstract][Full Text] [Related]
3. Med23 deficiency reprograms the tumor microenvironment to promote lung tumorigenesis.
Fu X; Liu S; Cao D; Li C; Ji H; Wang G
Br J Cancer; 2024 Mar; 130(5):716-727. PubMed ID: 38195889
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of mediator MED23 in non-small-cell lung cancer promotes the growth, migration, and metastasis of cancer cells.
Shi J; Liu H; Yao F; Zhong C; Zhao H
Tumour Biol; 2014 Dec; 35(12):12005-13. PubMed ID: 25273169
[TBL] [Abstract][Full Text] [Related]
5. C-Raf is required for the initiation of lung cancer by K-Ras(G12D).
Karreth FA; Frese KK; DeNicola GM; Baccarini M; Tuveson DA
Cancer Discov; 2011 Jul; 1(2):128-36. PubMed ID: 22043453
[TBL] [Abstract][Full Text] [Related]
6. Mediator MED23 regulates basal transcription in vivo via an interaction with P-TEFb.
Wang W; Yao X; Huang Y; Hu X; Liu R; Hou D; Chen R; Wang G
Transcription; 2013; 4(1):39-51. PubMed ID: 23340209
[TBL] [Abstract][Full Text] [Related]
7. Kruppel-like factor 5 is not required for K-RasG12D lung tumorigenesis, but represses ABCG2 expression and is associated with better disease-specific survival.
Meyer SE; Hasenstein JR; Baktula A; Velu CS; Xu Y; Wan H; Whitsett JA; Gilks CB; Grimes HL
Am J Pathol; 2010 Sep; 177(3):1503-13. PubMed ID: 20639455
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors.
Symonds JM; Ohm AM; Carter CJ; Heasley LE; Boyle TA; Franklin WA; Reyland ME
Cancer Res; 2011 Mar; 71(6):2087-97. PubMed ID: 21335545
[TBL] [Abstract][Full Text] [Related]
9. Mediator MED23 links insulin signaling to the adipogenesis transcription cascade.
Wang W; Huang L; Huang Y; Yin JW; Berk AJ; Friedman JM; Wang G
Dev Cell; 2009 May; 16(5):764-71. PubMed ID: 19460352
[TBL] [Abstract][Full Text] [Related]
10. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.
Chou YT; Lin HH; Lien YC; Wang YH; Hong CF; Kao YR; Lin SC; Chang YC; Lin SY; Chen SJ; Chen HC; Yeh SD; Wu CW
Cancer Res; 2010 Nov; 70(21):8822-31. PubMed ID: 20978205
[TBL] [Abstract][Full Text] [Related]
11. Mediator MED23 plays opposing roles in directing smooth muscle cell and adipocyte differentiation.
Yin JW; Liang Y; Park JY; Chen D; Yao X; Xiao Q; Liu Z; Jiang B; Fu Y; Bao M; Huang Y; Liu Y; Yan J; Zhu MS; Yang Z; Gao P; Tian B; Li D; Wang G
Genes Dev; 2012 Oct; 26(19):2192-205. PubMed ID: 22972934
[TBL] [Abstract][Full Text] [Related]
12. Mediator subunit 23 overexpression as a novel target for suppressing proliferation and tumorigenesis in hepatocellular carcinoma.
Guo Y; Wang J; Li H; Liu W; Chen D; Zhao K; Liang X; Zhang Q; Yang Y; Chen G
J Gastroenterol Hepatol; 2015 Jun; 30(6):1094-103. PubMed ID: 25684393
[TBL] [Abstract][Full Text] [Related]
13. ERK phosphorylation of MED14 in promoter complexes during mitogen-induced gene activation by Elk-1.
Galbraith MD; Saxton J; Li L; Shelton SJ; Zhang H; Espinosa JM; Shaw PE
Nucleic Acids Res; 2013 Dec; 41(22):10241-53. PubMed ID: 24049075
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
15. The ARF tumor-suppressor controls Drosha translation to prevent Ras-driven transformation.
Kuchenreuther MJ; Weber JD
Oncogene; 2014 Jan; 33(3):300-7. PubMed ID: 23318441
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of MED23 promoted the tumorigenecity of esophageal squamous cell carcinoma.
Shi J; Han Q; Zhao H; Zhong C; Yao F
Mol Carcinog; 2014 Oct; 53(10):833-40. PubMed ID: 23625751
[TBL] [Abstract][Full Text] [Related]
17. The Mediator Med23 controls a transcriptional switch for muscle stem cell proliferation and differentiation in muscle regeneration.
Fang Y; Yuan C; Li C; Lu C; Yu W; Wang G
Cell Rep; 2024 May; 43(5):114177. PubMed ID: 38691453
[TBL] [Abstract][Full Text] [Related]
18. Liver Med23 ablation improves glucose and lipid metabolism through modulating FOXO1 activity.
Chu Y; Gómez Rosso L; Huang P; Wang Z; Xu Y; Yao X; Bao M; Yan J; Song H; Wang G
Cell Res; 2014 Oct; 24(10):1250-65. PubMed ID: 25223702
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic Ras-mediated downregulation of Clast1/LR8 is involved in Ras-mediated neoplastic transformation and tumorigenesis in NIH3T3 cells.
Ryu SH; Kim KH; Kim HB; Kim MH; Kim NH; Kang Y; Hyun JW; Seo HJ; Jun JY; You HJ
Cancer Sci; 2010 Sep; 101(9):1990-6. PubMed ID: 20550525
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer.
Sunaga N; Imai H; Shimizu K; Shames DS; Kakegawa S; Girard L; Sato M; Kaira K; Ishizuka T; Gazdar AF; Minna JD; Mori M
Int J Cancer; 2012 Apr; 130(8):1733-44. PubMed ID: 21544811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
